Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2CNS 1

Conditions

von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Kidney Neoplasms 1Hemangioblastoma 1Glioblastoma 1Adenoma, Islet Cell 1

Interventions

Radiosurgery 33Radiotherapy 19Temozolomide 16Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 7Cyclophosphamide 7trastuzumab deruxtecan 4temsirolimus 4Sunitinib 4Specimen Handling 4Mental Status and Dementia Tests 4motexafin gadolinium 3fludarabine phosphate 3fludarabine 3aldesleukin 3Trastuzumab 3Pemetrexed 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Dexamethasone 3Capecitabine 3Bevacizumab 3pembrolizumab 2entrectinib 2efaproxiral 2Vinorelbine 2Topotecan 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Quality of Life 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × belzutifan × CNS × Clear all
NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡